Starpath Ventures - Investor Profile and Portfolio

Provider of identity threat protection, remediation, and cybercrime investigation solutions. The company uncovers identity risks from data breaches, malware infections, and phishing attacks. It integrates with existing tools to disrupt cybercrimes stemming from exposed employee, consumer, and third-party identities. The company offers enterprise and consumer protection, investigations, and data partnerships.

Offers blockchain-based caller ID app. The app notifies the caller ID to the customers. It also provides rewards in the form of bitcoins. It has features like visual caller ID, business caller ID, and spam blocking. The app is available on the Android platform.

Knopp Biosciences is a developer of small-molecule therapeutics for the treatment of CNS and inflammatory diseases. It's lead candidate dexpramipexole targets mitochondrial function has completed phase II trials for hypereosinophilic syndrome, chronic rhinosinusitis and Amyotrophic lateral sclerosis. In addition, the company is evaluating further candidates for neuropathic pain and epilepsy.

Developer of devices for cardiopulmonary therapies. The company is developing a device offering nitric oxide (NO) from iridium electrodes for infant acute pulmonary hypertension, heart, and lung therapies. The inhaled nitric oxide therapy delivery system relaxes the blood vessels lowering the blood pressure.